On the same day that Iovance Biotherapeutics disclosed that it received additional data requests on potency assays for its lead candidate lifileucel from the FDA, its chief executive Maria Fardis, Ph.D., told the company she'd be leaving.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,